Thomas Filleron

11.7k total citations
222 papers, 4.9k citations indexed

About

Thomas Filleron is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Thomas Filleron has authored 222 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 43 papers in Surgery. Recurrent topics in Thomas Filleron's work include Lung Cancer Treatments and Mutations (33 papers), Cancer Genomics and Diagnostics (26 papers) and Statistical Methods in Clinical Trials (25 papers). Thomas Filleron is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Cancer Genomics and Diagnostics (26 papers) and Statistical Methods in Clinical Trials (25 papers). Thomas Filleron collaborates with scholars based in France, United States and Italy. Thomas Filleron's co-authors include Philippe Rochaix, Sophie Le Guellec, Ludovic Martinet, Ignacio Garrido, Jean‐Philippe Girard, Julia Gilhodes, Nicolás Meyer, Jean‐Jacques Fournié, Elisabeth Bellard and Florence Dalenc and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Thomas Filleron

206 papers receiving 4.9k citations

Peers

Countries citing papers authored by Thomas Filleron

Since Specialization

Citations

This map shows the geographic impact of Thomas Filleron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Filleron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Filleron more than expected).

Fields of papers citing papers by Thomas Filleron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Filleron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Filleron. The network helps show where Thomas Filleron may publish in the future.

Co-authorship network of co-authors of Thomas Filleron

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Filleron. A scholar is included among the top collaborators of Thomas Filleron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Filleron. Thomas Filleron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients 2025 ·BJUI Compass ·(unknown), Aude Fléchon, G. Pignot, (unknown), J. Rigaud, M. Roumiguié, (unknown), Constance Thibault, Laurence Crouzet, (unknown), (unknown), Marine Gross‐Goupil, Luca Campedel, Mathieu Laramas, Thomas Filleron, E. Martin, Léonor Chaltiel, Damien Pouessel	0
2	Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy 2023 ·Respiratory Medicine and Research ·Clarisse Audigier-Valette, Thomas Filleron, D. Debieuvre, H. Léna, M. Pérol, C. Chouaïd, (unknown), Xavier Quantin, Nicolas Girard	5
3	Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol 2023 ·European Urology Oncology ·Giorgio Calleris, Thomas Filleron, Claudia Kesch, Guilhem Roubaud, Benjamin Pradère, Bastien Cabarrou, Bernard Malavaud, Morgan Rouprêt, Loı̈c Mourey, Guillaume Ploussard	0
4	Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Julia Gilhodes, (unknown), Bastien Cabarrou, (unknown), Thomas Filleron, (unknown), (unknown), V. Feillel, (unknown), (unknown), (unknown), (unknown), Fabienne Thomas, Laurence Gladieff, Christine Toulas	1
5	Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors 2023 ·Lung Cancer ·Pierre-Étienne Heudel, Anne Montfort, D. Debieuvre, C. Chouaïd, Matthieu Carton, Clarisse Audigier-Valette, Thomas Filleron, Sylvie Chabaud, (unknown), Xavier Quantin, Sandrine Hiret, L. Bosquet, Jean‐Yves Blay	0
6	New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials 2023 ·Statistics in Medicine ·Jean‐Marie Boher, Thomas Filleron, Pierre Bunouf, Richard J. Cook	0
7	1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France 2023 ·Annals of Oncology ·D. Debieuvre, (unknown), Xavier Quantin, (unknown), Nicolas Girard, Clarisse Audigier-Valette, Thomas Filleron, (unknown), L. Bosquet, M. Pérol	1
8	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial 2020 ·Clinical Cancer Research ·Anne Montfort, Thomas Filleron, (unknown), (unknown), (unknown), Cécile Pagès, Pascale Olivier, Maha Ayyoub, (unknown), Amélie Lusque, Stéphanie Brayer, Jean‐Pierre Delord, Nathalie Andrieu‐Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, Nicolás Meyer	70
9	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy 2019 ·Breast Cancer Research and Treatment ·William Jacot, Florence Dalenc, Evelyne Lopez‐Crapez, Léonor Chaltiel, (unknown), (unknown), (unknown), (unknown), Stéphane Pouderoux, Laurence Gladieff, Gilles Romieu, Henri Roché, Thomas Filleron, Pierre‐Jean Lamy	18
10	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas 2018 ·Molecular Cancer Therapeutics ·David Garandeau, (unknown), J. C. Leclerc, Caroline Imbert, Virginie Garcia, Marie‐Lise Bats, Florian Rambow, Julia Gilhodes, Thomas Filleron, Nicolás Meyer, Stéphanie Brayer, (unknown), Sophie Tartare‐Deckert, Bruno Ségui, Jean‐Christophe Marine, Thierry Levade, Corine Bertolotto, Nathalie Andrieu‐Abadie	26
11	Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells 2018 ·Molecular Cancer Research ·Laure Malric, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, (unknown), (unknown), (unknown), (unknown), Julia Gilhodes, Thomas Filleron, Aurore Siegfried, Solène Evrard, Aline Kowalski‐Chauvel, Elizabeth Cohen‐Jonathan Moyal, Christine Toulas, Anthony Lemarié	28
12	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study 2017 ·Clinical Lung Cancer ·Carole Massabeau, Jonathan Khalifa, Thomas Filleron, A. Modesto, L. Bigay-Gamé, Gavin Plat, Lawrence Dierickx, R. Aziza, Isabelle Rouquette, Carlos Gomez‐Roca, (unknown), Jean‐Pierre Delord, Christine Toulas, Pascale Olivier, Étienne Chatelut, Julien Mazières, Elizabeth Cohen‐Jonathan Moyal	21
13	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations 2016 ·Cancer Research ·Yu Fu, Cécile Jovelet, Thomas Filleron, Marion Pedrero, Nelly Motté, Yannick Boursin, (unknown), Christophe Massard, Mario Campone, Christelle Lévy, Véronique Dièras, Thomas Bachelot, Julie Garrabey, Jean‐Charles Soria, Ludovic Lacroix, Fabrice André, Céline Lefèbvre	11
14	Lésions épithéliales précoces dans les annexectomies prophylactiques chez des patientes à haut risque de cancer de l’ovaire : à propos d’une série de 93 cas 2015 ·Gynécologie Obstétrique & Fertilité ·(unknown), Gwénaël Ferron, Thomas Filleron, Denis Querleu, Eliane Mery-Lamarche	2
15	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort 2015 ·Annals of Oncology ·Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi	219
16	RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer 2014 ·Clinical Cancer Research ·Olivier Calvayrac, Anne Pradines, Isabelle Raymond‐Letron, Isabelle Rouquette, Emilie Bousquet, Valérie Lauwers‐Cancès, Thomas Filleron, J. Cadranel, Michèle Beau‐Faller, (unknown), Julie Milia, Gilles Favre, Julien Mazières	18
17	Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer 2011 ·Cancer Research ·Ludovic Martinet, Ignacio Garrido, Thomas Filleron, Sophie Le Guellec, Elisabeth Bellard, Jean‐Jacques Fournié, Philippe Rochaix, Jean‐Philippe Girard	387
18	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro- D -glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer 2010 ·Clinical Cancer Research ·S. Vergèz, Jean‐Pierre Delord, Fabienne Thomas, Philippe Rochaix, (unknown), Thomas Filleron, (unknown), Pierre Canal, F. Courbon, Ben Allal	20
19	Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis 2010 ·Clinical Cancer Research ·Florence Dalenc, Sophie Doisneau-Sixou, Ben Allal, (unknown), Valérie Lauwers‐Cancès, Karima Chaoui, Odile Burlet‐Schiltz, Bernard Monsarrat, Thomas Filleron, N. Renée, (unknown), (unknown), Gilles Favre, Henri Roché	21
20	Brachytherapy in Lip Carcinoma: Long-Term Results 2010 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), S. Vergèz, Michel Rives, Thomas Filleron, Jacques Bonnet, M. Delannes	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact